Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155676 | 0.87 | MEN1 (0.49) | GRM5ALDH1A1MEN1NPC1GAA | |
| SCHEMBL11469033 | 0.86 | GRM5 (0.47) | GRM5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL20203727 | 0.79 | SCN5A (0.64) | GRM5ALDH1A1NPC1GAARAB9A | |
| SCHEMBL937590 | 0.78 | SCN5A (0.62) | ALDH1A1TLR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22044433 | 0.72 | MEN1 (0.51) | GRM5ALDH1A1MEN1NPC1GAA | |
| SCHEMBL11478524 | 0.71 | GRM5 (0.39) | GRM5ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL937686 | 0.70 | TNK2 (0.44) | GRM5ALDH1A1FYNMEN1NPC1 | |
| SCHEMBL2018913 | 0.69 | TNK2 (0.46) | GRM5ALDH1A1FYNGAA | |
| SCHEMBL6406035 | 0.68 | LTA4H (0.75) | TLR8NPC1RAB9ALTA4H | |
| SCHEMBL2860844 | 0.68 | LTA4H (0.75) | TLR8NPC1RAB9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | TYMP, TK1, DPYD | GRM5 3125/4885ALDH1A1 1353/4885TLR8 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.